-
公开(公告)号:US11724979B2
公开(公告)日:2023-08-15
申请号:US17377125
申请日:2021-07-15
发明人: Imre Juhász , Irén Hortobágyi , Tamás Altsach , István Lászlófi , Ágnes Nagyné Borkó , Imre Rozsumberszki , Gábor Havasi , Zsuzsanna Kardos , Péter Buzder-Lantos
IPC分类号: C07C51/347 , C07C41/26 , C07C45/30 , C07C45/65 , C07C51/09 , C07C51/41 , C07C67/14 , C07C67/29 , C07C67/293 , C07C69/76 , C07C41/30 , C07C41/48 , C07C43/315 , C07C13/547 , C07C35/37 , C07C59/72
CPC分类号: C07C51/347 , C07C13/547 , C07C35/37 , C07C41/26 , C07C41/30 , C07C41/48 , C07C43/315 , C07C45/30 , C07C45/305 , C07C45/65 , C07C51/09 , C07C51/412 , C07C59/72 , C07C67/14 , C07C67/29 , C07C67/293 , C07C69/76 , C07C2603/14 , C07C45/305 , C07C49/84 , C07C45/30 , C07C49/84 , C07C45/65 , C07C49/755 , C07C51/09 , C07C59/70 , C07C41/48 , C07C43/315 , C07C67/14 , C07C69/76 , C07C67/29 , C07C69/76 , C07C67/293 , C07C69/76 , C07C51/412 , C07C59/70
摘要: Treprostinil is a synthetic prostacyclin derivative with thrombocyte aggregation inhibitory and vasodilatory activity. Treprostinil can be administered in subcutaneous, intravenous, inhalable, or oral forms. Disclosed is a method for the preparation of treprostinil of formula I and its amorphous form, anhydrate form, monohydrate form, and polyhydrate form salts with bases. In the disclosed method, the chiral center in the 3-hydroxyoctyl substituent is formed at the end of the synthesis, so that the method is robust and well scalable. Also disclosed are treprostinil intermediates and the preparation of the intermediates.
-
公开(公告)号:US10322990B2
公开(公告)日:2019-06-18
申请号:US15518096
申请日:2015-09-28
发明人: Imre Juhász , Irén Hortobágyi , Tamás Altsach , István Lászlófi , Ágnes Nagyné Borkó , Imre Rozsumberszki , Gábor Havasi , Zsuzsanna Kardos , Péter Buzder-Lantos
IPC分类号: C07C51/347 , C07C41/26 , C07C45/30 , C07C45/65 , C07C51/09 , C07C51/41 , C07C67/14 , C07C67/29 , C07C67/293 , C07C69/76 , C07C41/30 , C07C41/48 , C07C43/315 , C07C13/547 , C07C35/37 , C07C59/72
摘要: Treprostinil is a synthetic prostacyclin derivative with thrombocyte aggregation inhibitory and vasodilatory activity. Treprostinil can be administered in subcutaneous, intravenous, inhalable, or oral forms. Disclosed is a method for the preparation of treprostinil of formula I and its amorphous form, anydrate form, monohydrate form, and polyhydrate form salts with bases. In the disclosed method, the chiral center in the 3-hydroxyoctyl substituent is formed at the end of the synthesis, so that the method is robust and well scalable. Also disclosed are treprostinil intermediates and the preparation of the intermediates.
-
公开(公告)号:US11098001B2
公开(公告)日:2021-08-24
申请号:US16397139
申请日:2019-04-29
发明人: Imre Juhász , Irén Hortobágyi , Tamás Altsach , István Lászlófi , Ágnes Nagyné Borkó , Imre Rozsumberszki , Gábor Havasi , Zsuzsanna Kardos , Péter Buzder-Lantos
IPC分类号: C07C51/347 , C07C41/26 , C07C45/30 , C07C45/65 , C07C51/09 , C07C51/41 , C07C67/14 , C07C67/29 , C07C67/293 , C07C69/76 , C07C41/30 , C07C41/48 , C07C43/315 , C07C13/547 , C07C35/37 , C07C59/72
摘要: Treprostinil is a synthetic prostacyclin derivative with thrombocyte aggregation inhibitory and vasodilatory activity. Treprostinil can be administered in subcutaneous, intravenous, inhalable, or oral forms. Disclosed is a method for the preparation of treprostinil of formula I and its amorphous form, anhydrate form, monohydrate form, and polyhydrate form salts with bases. In the disclosed method, the chiral center in the 3-hydroxyoctyl substituent is formed at the end of the synthesis, so that the method is robust and well scalable. Also disclosed are treprostinil intermediates and the preparation of the intermediates.
-
公开(公告)号:US10442762B2
公开(公告)日:2019-10-15
申请号:US15780896
申请日:2016-11-10
发明人: Péter Buzder-Lantos , Zsuzsanna Kardos , Irén Hortobágyi , István Lászlófi , Imre Juhász , László Fónagy , Csaba Váradi , Ágnes Nagyné Borkó
IPC分类号: C07C405/00 , B01D15/26 , B01D15/42 , B01J20/10 , C07C7/12
摘要: The subject of the invention is a novel process for the preparation of Carboprost tromethamine salt where alkylation the enone of the general formula (II) is carried out in the presence of a chiral auxiliary in aprotic solvent with a Grignard reagent. The methyl ester epimers of formula (VII) are separated by gravity silica gel chromatography and the salt formation is carried out by using solid tromethamine base.
-
-
-